Sulzer Medica reports strong first quarter:
This article was originally published in Clinica
Executive Summary
Swiss company Sulzer Medica has seen sales rise 21% to SwFr 346 million ($235 million) in the first quarter. Adjusted for beneficial currency moves, the rise is 9%. The cardiovascular prosthesis division performed best, increasing 33% to SwFr 52 million, followed by pacemakers, up 22% to SwFr 112 million, and orthopaedics, up 17% to SwFr 184 million. In the summer, Sulzer Medica is planning to offer a quarter of its shares to the public in the US and Switzerland.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.